Ambu has seen its share price move around sharply over recent years, which raises a simple question for you as an investor. Is the current price around these levels really aligned with the cash the business is expected to generate over time, or has sentiment moved further than its cash flows justify?
-
Over the past 5 years the stock has fallen 54.7%, which puts the focus squarely on whether the cash Ambu can produce in future supports even the current valuation.
-
The company's value story now leans heavily on how efficiently it can turn its medical device portfolio into reliable free cash flow, since that ultimately funds investment, debt service and any potential shareholder returns.
-
Prefer to judge Ambu on earnings? See why Ambu's 41.2x P/E tells a different valuation story .
The stock's next move may depend on whether Ambu's current share price fairly reflects the intrinsic value suggested by its cash flows.
If you want a wider yardstick for Ambu's cash flow story, compare it with companies in 195 high quality undervalued stocks .
Is Ambu a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here looks at the cash Ambu can return to shareholders over time and discounts it back to today. On this view, the business is already producing material cash, with latest twelve month free cash flow of about DKK 519.8 million. The projections assume that this pool of cash grows rather than shrinks over the coming years.
The forecast path points to recovering and then growing free cash flow in DKK, with estimates reaching into the low single digit billions over the next decade. Against a current share price of DKK80.50, the DCF output suggests Ambu's estimated intrinsic value is substantially above the current share price. This implies the market is putting a cautious tag on those future cash flow assumptions. You can see how that gap is calculated, and stress test the cash flow inputs for yourself, in the full model view. Find out what Ambu could be worth using our Discounted Cash Flow (DCF) estimate .
The Ambu Narrative: What Would Justify Today's Price?
Narratives for Ambu pick up where the cash flow puzzle leaves off and spell out which paths for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than it is today. Where a single ratio or DCF result gives one headline figure, these scenarios unpack the future that number relies on, so you can watch in real time whether Ambu's actual progress keeps lining up with that story on Simply Wall St's Community page.
Community views on Ambu split around whether current expectations already bake in the good news or still underplay what the business can deliver.
Bull case: 28% undervalued
"Continued structural conversion from reusable to single use endoscopy across respiratory and urology procedures can widen Ambu's procedure base beyond what linear Endoscopy revenue forecasts imply..."
Discover why this Narrative puts Ambu at 28% undervalued .
Bear case: 32% overvalued
"While Ambu highlights strong single use endoscopy growth, the updated full year guidance to around 10% organic revenue growth with very low single digit Anesthesia and Patient Monitoring growth indicates that weaker anesthesia demand and pricing sensitivity could cap overall revenue growth..."
Explore why this Narrative puts Ambu at 32% overvalued .
Ambu's valuation still leaves one crucial angle open
Cash flows tell you what Ambu is worth on paper, but the people choosing where each krone goes and how they are rewarded can tilt that story in very different directions. See who runs Ambu and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMBU-B.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
